Comparative Pharmacology
Head-to-head clinical analysis: IV PERSANTINE versus MINOXIDIL EXTRA STRENGTH FOR MEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IV PERSANTINE versus MINOXIDIL EXTRA STRENGTH FOR MEN.
IV PERSANTINE vs MINOXIDIL EXTRA STRENGTH (FOR MEN)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits adenosine deaminase and phosphodiesterase, increasing intracellular cAMP and adenosine; causes coronary vasodilation and inhibits platelet aggregation.
Minoxidil is a potassium channel opener that causes direct vasodilation of peripheral arterioles. It increases blood flow to hair follicles and prolongs the anagen (growth) phase of hair follicles.
0.14 mg/kg/min intravenous infusion over 4 minutes for myocardial perfusion imaging.
Topical: 1 mL of 5% solution (50 mg) applied to the scalp twice daily. Maximum daily dose: 2 mL (100 mg).
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours in adults; may be prolonged in patients with hepatic impairment.
Terminal elimination half-life is approximately 4.2 hours in patients with normal renal function. However, the pharmacodynamic half-life (duration of antihypertensive effect) is about 24 hours, allowing once-daily dosing.
Primarily hepatic metabolism (glucuronidation) with enterohepatic recirculation; renal excretion of unchanged drug is minimal (<1%); biliary/fecal elimination accounts for approximately 90% of the dose.
Primarily renal (approximately 95% as parent drug and metabolites). Biliary/fecal excretion is minimal (less than 5%).
Category C
Category A/B
Vasodilator
Vasodilator / Hair Growth Stimulant